Dopaminergic alterations in patients with Alzheimer’s disease
Objective: The objective of this study was to conduct a meta-analysis to determine the pooled mean difference (MD) in dopaminergic measures between Alzheimer’s disease and…In Silico Electrophysiology and System Pharmacology Reveal Coupling Between Dopamine Receptors and Ca2+ Channels in Subthalamic Neuronal Cells towards Parkinson’s Disease
Objective: Recent experimental evidence suggests a potential interaction between dopamine D2 receptors (D2R) and N-type Ca2+ channels, impacting the firing patterns of Subthalamic neuronal (STN)…Long-term safety and durability of effect of ecopipam in pediatric patients with Tourette Syndrome: Results of a 12-month open-label extension (OLE) study
Objective: Assess the safety and durability of effect of long-term treatment with ecopipam in pediatric patients with Tourette syndrome (TS). Background: TS is a childhood-onset…Dopamine Receptor Gene Polymorphism in L-Dopa Induced Dyskinesia- A Study from Eastern India
Objective: We intended to find the frequency of Single Nucleotide Polymorphism (SNP) rs6280 in DRD3 gene in PD patients with and without Levodopa Induced Dyskinesia…Identification of xylopropamine as a potential dopamine D2 receptor agonist through computational drug discovery pipeline
Objective: This study aims to identify novel dopamine D2 receptor agonists through the computational drug discovery pipeline. Background: Parkinson's disease (PD) is a neurodegenerative disorder…Quantification of Striatal and Extrastriatal Dopamine Transporters with [18F]PR04.MZ and [18F] PI- 2620 PET in Patients with Progressive Supranuclear Palsy.
Objective: We aim to evaluate the differences in striatal subregional dopamine transporter loss between Parkinson disease (PD) and progressive supranuclear palsy (PSP) of any stage…Preclinical characterization of UCB0022, an oral, brain penetrant, selective, clinical-stage positive allosteric modulator of the dopamine 1 receptor (D1 PAM)
Objective: To characterize the in vitro and in vivo pharmacologic profile of UCB0022 Background: Parkinson’s disease (PD) is a progressive neurodegenerative disease with reductions in…PP1α negatively regulates D2 receptor mediated cadmium induced motor dysfunctions: protective potential of Quercetin.
Objective: The present study has been focused to identify the molecular targets that involved in Cadmium-induced motor dysfunctions. At the same time, we also focused…The study of genetic factors in motor levodopa-induced complications development in Russian patients with Parkinson’s disease
Objective: This study is aimed to explore the relationship between the single nucleotide polymorphisms (SNPs) in dopamine metabolism genes and development of motor side effects…Using a Dopamine Genetic Risk Score to Predict Impulse Control Behaviours for Parkinson’s Disease Patients
Objective: The current study aimed to utilise a dopamine genetic risk score and objective laboratory-based behavioural measures of impulse control to identify Parkinson’s patients most…
- 1
- 2
- 3
- …
- 5
- Next Page »